Catalyst Pharmaceuticals Releases First ESG Report

Published on:
by KnowESG
KnowESG_Catalyst Pharmaceuticals
Image courtesy of https://moffitt.org/

Catalyst Pharmaceuticals, a biopharmaceutical company that develops and commercialises high-quality medicines for rare diseases, has released its first ESG Report.

This report promotes transparency and outlines Catalyst's practices in the ESG field, including sustainability, equity, and ensuring access to safe and affordable medicine for patients. It describes how the company navigates key issues related to its mission.

According to Catalyst's Chairman and CEO, Patrick J. McEnany, since the company's inception 20 years ago, its mission has always been to improve the lives of those with rare diseases. As Catalyst continues to grow and expand, the company must remain accountable and responsible. The release of their inaugural ESG report highlights their ESG strategy, key areas of focus, and significant progress.

It also outlines the evolution of their ESG journey and their commitment to responsible operations while pursuing growth initiatives and serving the patient community. Future reporting periods will provide further updates on Catalyst's ESG programme strategy as they deliver on strategic priorities and generate value for stakeholders.

Catalyst's ESG report emphasises the company's dedication to creating sustainable and collective value across various areas deemed material and impactful to its business by key stakeholders. Catalyst has aligned its ESG report with multiple reporting frameworks, including the Sustainability Accounting Standards Board (SASB), the Global Reporting Initiative (GRI), and the United Nations' Sustainable Development Goals (UN SDGs).

In 2022, Catalyst Pharmaceuticals made significant progress in formalising and advancing its ESG programme, including the release of its inaugural ESG report that identifies material ESG topics to prioritise the company's strategy moving forward.

Catalyst delivers on its promise of providing safe and effective drugs through expanded access programmes, innovative research and development practices, robust quality standards, affordability, and patient access.

The company ensures its employees follow the highest ethical standards, promotes transparency, and has established a formal ESG oversight structure.

Although Catalyst has a relatively low environmental footprint, it remains committed to reducing its impact across the organisation and value chain. Catalyst Pharmaceuticals' 2022 ESG Report is available on the company's website under the "Responsibility" section.

To view and compare company ESG Ratings and Sustainability Reports across sectors, follow our Company ESG Profiles page.

For more investor-related news

Source: Catalyst

Share:
esg
esg
esg
esg

Investors Headlines

Mizuho, LSEG Partner to Grow Carbon Credit Market

Mizuho, LSEG Partner to Grow Carbon Credit Market

Safran to Build a More Sustainable Aerospace Supply Chain

Safran to Build a More Sustainable Aerospace Supply Chain

ESG in Private Real Estate: Preqin & Measurabl Tie-Up

AIM Group Publishes First Sustainability Report

APSEZ Earns Top Ranks for Sustainability Efforts

IHS Towers Releases 2023 Sustainability Report

TriNet Earns Top ESG Rating from ISS ESG

PATRIZIA Strengthens ESG Team for Impact Investing

CapitaLand Investment Steps Up Sustainability Efforts

Sustainability Tops CEO Agendas for Growth, Says Survey